Bayer Submits Regulatory Applications for Oncology Treatment Investigational Combination of Aliqopa® (copanlisib) and rituximab in the U.S. and EU
Retrieved on:
Monday, June 21, 2021
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical trials, Branches of biology, Biology, Oncology, Cell signaling, Programmed cell death, Phosphoinositide 3-kinase, Signal transduction, Kinase, Apoptosis, Phosphoinositide 3-kinase inhibitor, PI3K/AKT/mTOR pathway, Aliqopa® (copanlisib) Injection, non-Hodgkin’s Lymphoma, Oncology at Bayer, Bayer, ALIQOPA® (COPANLISIB) INJECTION, NON-HODGKIN’S LYMPHOMA, ONCOLOGY AT BAYER, BAYER
In the EU, Bayer has filed for the treatment of relapsed marginal zone lymphoma (MZL), a subtype of iNHL, and the filing has been accepted.
Key Points:
- In the EU, Bayer has filed for the treatment of relapsed marginal zone lymphoma (MZL), a subtype of iNHL, and the filing has been accepted.
- Aliqopa is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3K- and PI3K- isoforms expressed in malignant B cells.
- Aliqopa has been shown to induce tumor cell death by apoptosis and inhibition of proliferation of primary malignant B cell lines.
- The clinical development program for Aliqopa also includes the Phase III study CHRONOS-4, evaluating Aliqopa in combination with standard immunochemotherapy in relapsed iNHL.